Search

671 Result(s)
Sort by

CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Lung Cancer

Lung Cancer

Find out more about lung cancer, the second most common cancer worldwide, that claims more lives each year than any other type.
Small Cell Lung Cancer

Small Cell Lung Cancer

Discover more about small cell lung cancer, including its symptoms and treatment options.
Non-small cell lung cancer

Non-small cell lung cancer

Discover more about non-small cell lung cancer, including its symptoms and treatment options.
Breaking prejudice in lung cancer

Breaking prejudice in lung cancer

At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Lung Repair & Regeneration Video

Lung Repair & Regeneration Video

Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Facing lung cancer

Facing lung cancer

Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.